CAMP4 Closes $50M Second Tranche of Private Placement at $1.53/Share
CAMP has more than doubled off its 52-week low of $1.32.
Summary
CAMP4 completed the second closing of its previously announced private placement, raising $50.1 million in gross proceeds. The financing included 10.76 million shares at $1.53, plus pre-funded warrants, with participation from notable biotech investors including Janus Henderson and Vivo Capital. This follows the company's recent Australian clearance to begin a Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, and the proceeds are earmarked to advance that program. The pricing represents a significant discount to the current $4.12 market price, but the capital extends the runway for a company that had a reduced cash position as of Q1 2026. The deal structure and investor roster suggest institutional support despite the dilutive terms.
At the time of this announcement, CAMP was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.6M. The 52-week trading range was $1.32 to $7.75. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.